Issue Archive
Table of Contents
INSIDE BLOOD
REVIEW ARTICLES
HOW I TREAT
CLINICAL TRIALS AND OBSERVATIONS
Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study
Clinical Trials & Observations
The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients
Brief Report
GENE THERAPY
HEMATOPOIESIS AND STEM CELLS
IMMUNOBIOLOGY
LYMPHOID NEOPLASIA
Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance
Extensive intraclonal diversification in a subgroup of chronic lymphocytic leukemia patients with stereotyped IGHV4-34 receptors: implications for ongoing interactions with antigen
Chronic lymphocytic leukemia of Eμ-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression
A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display
MYELOID NEOPLASIA
PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS
GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-α converting enzyme (TACE)
PLATELETS AND THROMBOPOIESIS
RED CELLS, IRON, AND ERYTHROPOIESIS
THROMBOSIS AND HEMOSTASIS
Recombinant canine B-domain–deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model
Brief Report
TRANSPLANTATION
VASCULAR BIOLOGY
A novel interplay between Epac/Rap1 and mitogen-activated protein kinase kinase 5/extracellular signal-regulated kinase 5 (MEK5/ERK5) regulates thrombospondin to control angiogenesis
CORRESPONDENCE
ERRATA
-
Cover Image
Cover Image
Iron chelators trap iron being released from ferritin protein nanocages in the cytoplasm or dissolved from degraded ferritin/hemosiderin in lysosomes. Ferritin protein in the cytoplasm is degraded by proteosomes while ferritin in lysosomes is degraded by lysosomal hydrolases. De Domenico et al show that the chelator desferrioxamine targets ferritin/hemosiderin iron in lysosomes, while the chelators deferriprone and desferasirox target ferritin iron in the cytoplasm. Thus, the 2 different cell compartments where ferritin iron is mined are selectively targeted by the oral or injectable iron chelators in current use. Professional illustration by A. Y. Chen. See the commentary by Theil on page 4325 and the article by De Domenico et al on p 4546.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals